[1] YAGHOOBI R,0MIDIAN M,BAGHERANI N. Vitiligo:a review of the published work[J]. J Dermatol,2011,38(5):419-431. [2] 中国中西医结合学会皮肤性病专业委员会色素病学组.白癜风临床分型及疗效标准 [J]. 中华皮肤科杂志,2004,37(7):440. [3] ARYA RK,GUPTA DK,CHAUDHARY SC. A rare case of autoimmune polyglandular syndrome type IIIc[J]. Indian J Endoerinol Metab,2012,16(3):480. [4] 张孟丽,马鹏程.白癜风免疫学研究进展[J]. 中国美容医学,2011,20(7):1181-1183. [5] PICHLER R, SFETSOS K, BADICS B, et al. Lymphocyte imbalance in vitiligo patients indicated by elevated CD4C/CD8C T-cell ratio[J]. Wien Med Wochenschr,2009,159:337-341. [6] ZHOU L,LI K,SHI YL, et al. Systemic anaIyses of immunopheno-types of peripheralT ceIls in non-segmental vitiligo:implication of defective nalural killer T celIs[J]. Pigment cell Melanoma Res,2012,25(5):602-611. [7] YU HS, CHANG KL, YU CL, et al. Alterations in IL-6, IL-8, GM-CSF, TNF-alpha, and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo[J]. Invest Dermatol,1997,108:527-529. [8] ZAILAIE MZ. Decreased proinflammatory cytokine production by peripheral blood mononuclear cells from vitiligo patients following aspirin treatment[J]. Saudi Med,2005,26:799-805. [9] KIRNBAUER R, CHARVAT B, SCHAUER K, et al. Modulation of intercellular adhesion molecule-1 expression on human melanocytes and melanoma cells: Evidence for a regulatory role of IL-6, IL-7, TNF-α and UVB light[J]. Invest Dermatol,1992,98:320-326. [10] MORELLI JG, NORRIS DA. Influence of inflammatory mediators and cytokines on human melanocyte function[J]. Invest Dermatol,1993,100:191-195. [11] YEO UC, YANG YS, PARK KB, et al. Serum concentration of the soluble interleukin-2 receptor in vitiligo patients[J]. Dermatol Sci,1999,19:182-188. [12] GALADARI I. Serum levels of the soluble interleukin-2 receptor in vitiligo patients in UAE. Eur Ann Allergy[J]. Clin Immunol, 2005,37:109-111. |